Latest Probiotics News

EVE Health Group has announced a $1.3 million capital raising through a placement of shares and free attaching options, aimed at advancing its pharmaceutical product rollout and development pipeline. Several components of the offer await shareholder approval at an upcoming general meeting.

Terragen Holdings’ biostimulant Great Land Plus® has been independently shown to increase maize silage yields by up to 12%, translating into an estimated $1,100 additional revenue per hectare and a potential 20-fold return on investment.

Biome Australia Limited has reported a robust half-year performance, with revenues climbing nearly 40% and net profit more than doubling, driven by strong product momentum and strategic investments.

Terragen Holdings reports a 23% reduction in half-year net loss amid strategic shifts and completes a $7 million equity raise to accelerate global commercialisation of its biological agricultural products.

Terragen Holdings has raised A$7 million through a strategic equity raising to fund scientific research and accelerate global commercialisation, while appointing Dr Michele Allan AO as its new Chair.

Biome Australia has secured ethics approval to commence a pivotal human clinical trial of its proprietary probiotic strain BMB18, aiming to validate its benefits on digestive, sleep, and mood health.

Biome Australia has partnered with Fullscript to distribute its Activated Probiotics range across Canada, complementing its existing wholesale network and marking a key step in its international growth.

BPH Global has reported record sales in its Indonesian seaweed operations alongside completing a $1.1 million capital raise and advancing promising R&D projects. The company is scaling its trading platform and expanding into bio-stimulants and wellness products as it enters 2026.

Terragen Holdings reports a strong quarter with an 87% increase in sales of its ruminant probiotic and advances key livestock and crop trials, positioning itself for expanded market access.

Biome Australia Limited has delivered its strongest quarterly financial performance to date, with sales revenue surging 41% year-on-year to $6.5 million and maintaining eight consecutive quarters of positive EBITDA.

Biome Australia Limited has reported a record-breaking quarter and half-year sales performance, driven by strong demand for its clinically-backed probiotic products. Revenue surged over 40% compared to the previous year, defying typical seasonal slowdowns.

Biome Australia has initiated its first human clinical trial for the proprietary probiotic strain Lactobacillus plantarum BMB18, aiming to validate its benefits for digestive and mood-related symptoms.